1. Home
  2. PCRX vs AVXL Comparison

PCRX vs AVXL Comparison

Compare PCRX & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • AVXL
  • Stock Information
  • Founded
  • PCRX 2006
  • AVXL 2004
  • Country
  • PCRX United States
  • AVXL United States
  • Employees
  • PCRX N/A
  • AVXL N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PCRX Health Care
  • AVXL Health Care
  • Exchange
  • PCRX Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • PCRX 1.2B
  • AVXL 794.0M
  • IPO Year
  • PCRX 2011
  • AVXL N/A
  • Fundamental
  • Price
  • PCRX $23.22
  • AVXL $10.60
  • Analyst Decision
  • PCRX Buy
  • AVXL Strong Buy
  • Analyst Count
  • PCRX 8
  • AVXL 2
  • Target Price
  • PCRX $28.38
  • AVXL $44.00
  • AVG Volume (30 Days)
  • PCRX 569.8K
  • AVXL 942.8K
  • Earning Date
  • PCRX 07-29-2025
  • AVXL 08-05-2025
  • Dividend Yield
  • PCRX N/A
  • AVXL N/A
  • EPS Growth
  • PCRX N/A
  • AVXL N/A
  • EPS
  • PCRX N/A
  • AVXL N/A
  • Revenue
  • PCRX $702,772,000.00
  • AVXL N/A
  • Revenue This Year
  • PCRX $7.54
  • AVXL N/A
  • Revenue Next Year
  • PCRX $10.78
  • AVXL N/A
  • P/E Ratio
  • PCRX N/A
  • AVXL N/A
  • Revenue Growth
  • PCRX 3.08
  • AVXL N/A
  • 52 Week Low
  • PCRX $11.16
  • AVXL $4.00
  • 52 Week High
  • PCRX $27.64
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.42
  • AVXL 75.85
  • Support Level
  • PCRX $22.82
  • AVXL $9.08
  • Resistance Level
  • PCRX $24.36
  • AVXL $9.78
  • Average True Range (ATR)
  • PCRX 0.69
  • AVXL 0.53
  • MACD
  • PCRX -0.12
  • AVXL 0.19
  • Stochastic Oscillator
  • PCRX 17.09
  • AVXL 95.03

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: